title: Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer.
abstract: Because of their high affinity for bone, bisphosphonates are used both in the treatment of benign and malignant bone disease and in radiopharmaceutical bone imaging. A prospective study was undertaken to evaluate whether intravenous clodronate (dichloromethylene bisphosphonate) therapy might affect the results of bone scintigraphy with 99mTc-labeled methylene diphosphonate (MDP). In 11 female patients with breast cancer and metastatic bone disease, quantitative bone scans were obtained using a region of interest (ROI) method on Days 0 and 22. After intravenous clodronate therapy from Day 1 to Day 21, all metastatic bone lesions were still detectable, and median ROI ratios did not differ to a statistically significant extent from baseline values. Serum calcium levels decreased (p = 0.0449), whereas parathyroid hormone concentrations showed an increase (p = 0.0053). Mean serum levels of creatinine, inorganic phosphorus, osteocalcin, gamma glutaminyl-transpeptidase and alkaline phosphatase remained unchanged. However, a more than twofold rise in the serum activity of alkaline phosphatase was measured in three patients. We conclude that 3 wk of intravenous clodronate treatment did not impair the sensitivity of 99mTc-MDP bone scintigraphy in detecting bone lesions in patients with metastatic breast cancer.
authors.affiliation: Department of Oncology, Lainz Hospital, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Pecherstorfer
authors.forename: T
authors.initials: T
authors.lastname: Schilling
authors.forename: S
authors.initials: S
authors.lastname: Janisch
authors.forename: W
authors.initials: W
authors.lastname: Woloszczuk
authors.forename: G
authors.initials: G
authors.lastname: Baumgartner
authors.forename: R
authors.initials: R
authors.lastname: Ziegler
authors.forename: E
authors.initials: E
authors.lastname: Ogris
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000473:pathology*; D004002:Clodronic Acid / Q000627:therapeutic use*; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013669:Technetium Tc 99m Medronate; D013997:Time Factors
chemical_list: D004002:Clodronic Acid; D013669:Technetium Tc 99m Medronate